 | Up a level |
Pizzamiglio, S; Ciniselli, C M; de Azambuja, E; Agbor-Tarh, D; Moreno-Aspitia, A; Suter, T M; Trama, A; De Santis, M C; De Cecco, L; Iorio, M V; Silvestri, M; Pruneri, G; Verderio, P; Di Cosimo, S (2024). Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTO. Breast cancer research and treatment, 206(2), pp. 285-294. Springer 10.1007/s10549-024-07299-6
de Azambuja, E; Agostinetto, E; Procter, M; Eiger, D; Pondé, N; Guillaume, S; Parlier, D; Lambertini, M; Desmet, A; Caballero, C; Aguila, C; Jerusalem, G; Walshe, J M; Frank, E; Bines, J; Loibl, S; Piccart-Gebhart, M; Ewer, M S; Dent, S; Plummer, C; ... (2023). Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO open, 8(1), p. 100772. BMJ 10.1016/j.esmoop.2022.100772
